XenoTherapeutics Acquires Repare Therapeutics

Gilead Sciences Acquires XinThera

May 9, 2023

Biotechnology

Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.

Tome Biosciences Acquires Replace Therapeutics

January 5, 2024

Biotechnology

Tome Biosciences has acquired Replace Therapeutics in a merger valued at $65 million in up-front and near-term milestones and up to $185 million total through a mix of cash and stock. Replace will become a wholly owned subsidiary of Tome, adding its ligase-mediated programmable genomic integration (L-PGI) technology to complement Tome's large-DNA integrase-mediated PGI platform to expand the company's gene‑editing capabilities.

Aprea Therapeutics Acquires Atrin Pharmaceuticals

May 16, 2022

Biotechnology

Aprea Therapeutics, Inc. completed a stock-for-stock acquisition of privately held Atrin Pharmaceuticals, obtaining Atrin’s DNA damage response (DDR) oncology programs and proprietary discovery platform. The transaction expands Aprea’s pipeline (including ATRN-119, ATRN-354 and ATRN-W1051), adds Atrin leadership to Aprea’s management and board, and was structured to issue a mix of common stock and Series A preferred stock to former Atrin equity holders (who will own ~58.8% pro forma on an as-converted basis).

XenoTherapeutics Acquires ESSA Pharma

October 9, 2025

Pharmaceuticals

ESSA Pharma Inc.’s securityholders approved the acquisition of all issued and outstanding common shares of ESSA by XenoTherapeutics Inc. via a statutory plan of arrangement. The transaction is subject to Supreme Court of British Columbia approval and other customary closing conditions, with an expected court hearing on October 7, 2025 and completion around October 9, 2025.

Merck Acquires Caraway Therapeutics

November 21, 2023

Biotechnology

Merck (MSD) will acquire Caraway Therapeutics, a Cambridge, Massachusetts–based preclinical biopharmaceutical company, for up to $610 million in potential consideration, including an undisclosed upfront payment and contingent milestone payments. The acquisition is intended to strengthen Merck’s research pipeline and capabilities in developing small-molecule treatments for genetically defined neurodegenerative and rare diseases.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.